Disclaimer Notice:

Dear Readers! I started this blog when my daughter was in the NICU. She had ventriculitis. Her CSF report grew E.coli. But, she was injected Teicoplanin directly into her brain. The doctors made two errors here:

Teicoplanin is for gram-positive bacteria only. It does not treat E.coli.
Teicoplanin is not for intraventricular use. The manufacturer strongly discourage injecting Teicoplanin into the brain.

My daughter bled into the brain. She lived for another two years and ultimately died.

The information provided on Emedz.net is for doctors and pharmacists only to manage their patients in the best way and avoid medications-related errors.

Still, for the general population, this should not be considered professional medical advice or a substitute for consultation with a licensed healthcare provider. The content on this blog is not intended to diagnose, treat, cure, or prevent any disease or health condition.

Always seek the advice of a qualified healthcare professional before making any changes to your diet, exercise routine, medication, or any other aspect of your healthcare. We strongly discourage self-medication and self-treatment.

Even though the primary author of emedz.net is an experienced health professional, the blog is not intended to replace medical advice sought at the Doctor’s Clinic.

The authors share personal experiences, research findings, and general knowledge about health and wellness and medications-related topics.

However, individual health situations vary, and what works for one person may not work for another. It's important to consult with a healthcare provider for personalized guidance.

We strive to provide accurate and up-to-date information, but medical knowledge is constantly evolving. Therefore, we do not guarantee the accuracy, completeness, or timeliness of the information presented in this blog.

Emedz.net is not an online pharmacy:

Online pharmacies sell medicines and pharmaceutical products. EMEDZ.net is intended to provide drug-related information to pharmacists and physicians. It is intended to provide authentic information about medicines so as to prevent errors related to prescriptions.

We do not sell medicines, so please don’t ask for them.

We are not affiliated with any pharmaceutical companies:

Emedz.net has no affiliation with any pharmaceutical companies. We do not promote any product. Sometimes brand names are also mentioned in the title of the page, but that is what is called a “Featured Image”. It has nothing to do with selling or promoting that brand. Just to make things easier, generic and brands are mentioned in the blog.

Emedz.net may contain links to external websites or resources for your convenience. We do not endorse or take responsibility for the content of these external sites.

In no event shall Emedz.net, its authors, contributors, or any related parties be liable for any damages or consequences arising from the use of the information provided on this blog.

By using Emedz.net, you acknowledge and agree to this disclaimer and our Terms of Use. If you do not agree with this disclaimer or our Terms of Use, we advise you to refrain from using our website.

Remember, your health is a valuable asset, and decisions about your health should always be made in consultation with a qualified healthcare professional.

Telfast D (Fexofenadine and pseudoephedrine) - Uses, Dose, Brands

Fexofenadine and pseudoephedrine (Telfast D) are available as a single combination pill. It is used in the treatment of allergic symptoms primarily allergic rhinitis by acting as a decongestant and antihistamine.

Fexofenadine and pseudoephedrine Uses:

Seasonal allergic rhinitis:
- It is approved for the treatment of allergic rhinitis symptoms in people 12 years of age and older, including flu-like symptoms, sneezing, rhinitis, itching, red and watery eyes, nasal congestion, and an itchy throat.

Fexofenadine and pseudoephedrine (Telfast D) Dose in Adults

Fexofenadine and pseudoephedrine (Telfast D) Dose in the treatment of Seasonal allergic rhinitis: Oral:

Fexofenadine 60 mg/pseudoephedrine 120 mg 12 Hour:
- One tablet two times a day.
Fexofenadine 180 mg/pseudoephedrine 240 mg 24 Hour:
- One tablet once a day.

Dose in Children:

Refer to adult dosing.

Pregnancy Risk Factor C

Animal reproduction studies have shown adverse drug reactions and fetal outcomes.
Talk to individual agents.

Use of pseudoephedrine and fexofenadine during breastfeeding

Breast milk contains pseudoephedrine. It is unknown if breastmilk contains fexofenadine.
Check with individual agents. The manufacturer suggests that breastfeeding mothers use the drug with caution.

Dose in Kidney Disease:

Fexofenadine 60 mg/pseudoephedrine 120 mg 12 Hour:
- CrCl ≥80 mL/minute:
  - Adjustment in the dose is not necessary.
- CrCl <80 mL/minute:
  - Initial: One tablet once a day.
Fexofenadine 180 mg/pseudoephedrine 240 mg 24 Hour:
- Avoid its use.

Dose in Liver disease:

In the manufacturer’s labeling, dose adjustments have not been provided.

Side effects of Fexofenadine and pseudoephedrine (Telfast D):

See individual agents (fexofenadine and pseudoephedrine)

Contraindications to Fexofenadine and pseudoephedrine (Telfast D):

Allergy to pseudoephedrine, fexofenadine and other drugs that stimulate your sympathetic system, or any other drug of similar structure or any component of this formulation
Glaucoma with narrow angles
Urinary retention
Use within 14 days or concomitantly with MAO inhibitor treatment
Coronary heart disease and severe uncontrolled hypertension

Warnings and precautions

Cardiovascular disease
- It is not recommended for severe hypertension or coronary artery disease.
- Patients with heart disease, including those with moderate to severe hypertension and those with ischemic heart diseases, should be cautious.
Diabetes:
- Diabetes mellitus patients should be cautious when using the drug.
Increased intraocular pressure
- Patients with glaucoma or elevated intraocular pressure should be cautious.
Prostatic hyperplasia/urinary block:
- Patients suffering from genitourinary obstruction or prostatic hyperplasia must be cautious when taking the drug.
Renal impairment
- Patients with impaired renal function should be cautious when taking the drug.
Seizure disorder:
- It can stimulate the central nervous system. Patients with epilepsy or seizure disorders should be cautious when using the drug.
Thyroid dysfunction:
- Patients suffering from thyroid dysfunction should be cautious about taking the drug.

Fexofenadine and pseudoephedrine: Drug Interaction

Risk Factor C (Monitor therapy)
Acetylcholinesterase Inhibitors	May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.
Alcohol (Ethyl)	Alcohol's CNS depressing effect may be amplified by CNS depressants (Ethyl).
Alizapride	CNS depressants may have an enhanced CNS depressant impact.
Alkalinizing Agents	May raise the serum level of beta- and alpha-agonists (IndirectActing).
Alpha1-Blockers	May lessen the vasoconstriction caused by alpha/beta agonists. The vasodilation caused by Alpha1-Blocker may also be resisted by Alpha-/Beta-Agonists.
Amantadine	May strengthen an anticholinergic agent's anticholinergic action.
Amezinium	Antihistamines may intensify Amezinium's stimulant effects.
Amphetamines	May lessen antihistamines' sedative effects.
Anticholinergic Agents	Other anticholinergic agents' negative or hazardous effects might be amplified.
AtoMOXetine	May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.
Betahistine	Antihistamines may diminish the therapeutic effect of Betahistine.
Botulinum Toxin-Containing Products	May enhance the anticholinergic effect of Anticholinergic Agents.
Brexanolone	CNS Depressants may enhance the CNS depressant effect of Brexanolone.
Brimonidine (Topical)	May enhance the CNS depressant effect of CNS Depressants.
Bromopride	May enhance the CNS depressant effect of CNS Depressants.
Cannabidiol	May enhance the CNS depressant effect of CNS Depressants.
Cannabis	May enhance the CNS depressant effect of CNS Depressants.
Carbonic Anhydrase Inhibitors	May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).
Chloral Betaine	May worsen anticholinergic agents' harmful or hazardous effects.
Chloroprocaine	Alpha-/Beta-Agonists' hypertensive effects might be amplified.
Chlorphenesin Carbamate	May enhance the adverse/toxic effect of CNS Depressants.
CNS Depressants	May enhance the adverse/toxic effect of other CNS Depressants.
Dimethindene (Topical)	May enhance the CNS depressant effect of CNS Depressants.
Doxofylline	Sympathomimetics may enhance the adverse/toxic effect of Doxofylline.
Doxylamine	May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended.
Dronabinol	May enhance the CNS depressant effect of CNS Depressants.
Eltrombopag	May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates.
Erdafitinib	P-glycoprotein/ABCB1 Substrates serum levels can rise.
Erythromycin (Systemic)	Fexofenadine serum concentration can rise
Esketamine	CNS depressants may have an enhanced CNS depressant impact.
Gastrointestinal Agents (Prokinetic)	The therapeutic benefit of gastrointestinal agents may be diminished by anticholinergic agents (Prokinetic).
Gemfibrozil	May raise the level of OATP1B1/1B3 (SLCO1B1/1B3) Substrates in the serum.Agents indicated as exceptions should be examined in separate drug interaction monographs.
Glucagon	Anticholinergic drugs may make glucagon's harmful or toxic effects worse. Particularly, there may be a higher chance of unfavourable gastrointestinal consequences.
Grapefruit Juice	Fexofenadine's serum concentration can drop.
Guanethidine	Could make sympathomimetics more arrhythmogenic. Guanethidine might make sympathomimetic drugs more hypertensive.
HydrOXYzine	CNS depressants may have an enhanced CNS depressant impact.
Itopride	Itopride's therapeutic impact may be diminished by anticholinergic drugs.
Itraconazole	Fexofenadine serum concentration can rise.
Kava Kava	CNS depressants' harmful or toxic effects could be increased.
Ketoconazole (Systemic)	Fexofenadine serum concentration can rise.
Lofexidine	CNS depressants may have an enhanced CNS depressant impact. Management: Separate drug interaction monographs go into further detail about the medications indicated as exceptions to this book.
Lumacaftor	May lower the level of P-glycoprotein/ABCB1 Substrates in the serum. The serum concentration of P-glycoprotein/ABCB1 Substrates may rise when using lumacaftor.
Magnesium Sulfate	CNS depressants may have an enhanced CNS depressant impact.
MetyroSINE	The sedative effects of metyroSINE may be strengthened by CNS depressants.
Mianserin	May strengthen an anticholinergic agent's anticholinergic action.
Minocycline	CNS depressants may have an enhanced CNS depressant impact.
Mirabegron	Anticholinergic drugs may make Mirabegron's harmful or hazardous effects worse.
Mirtazapine	The CNS depressing action of mirtazapine may be enhanced by CNS depressants.
Nabilone	CNS depressants may have an enhanced CNS depressant impact.
Nitroglycerin	Nitroglycerin absorption may be decreased by anticholinergic agents.
P-glycoprotein/ABCB1 Inducers	May lower the level of Pglycoprotein/ABCB1 Substrates in the serum. P-glycoprotein inducers may also further restrict the distribution of p-glycoprotein substrates to particular cells, tissues, and organs that have high levels of p-glycoprotein (e.g., brain, T-lymphocytes, testes, etc.).
P-glycoprotein/ABCB1 Inhibitors	Pglycoprotein/ABCB1 Substrates serum levels can rise. Additionally, p-glycoprotein inhibitors may improve the distribution of pglycoprotein substrates to particular cells, tissues, and organs where high levels of p-glycoprotein are present (e.g., brain, T-lymphocytes, testes, etc.).
Piribedil	Piribedil's CNS depressing effects may be enhanced by other CNS depressants.
Pitolisant	Pitolisant's therapeutic effects may be lessened by antihistamines.
Pramipexole	The sedative effects of pramipexole might be enhanced by CNS depressants.
Ramosetron	Ramosetron's constipating effects may be enhanced by anticholinergic drugs.
Ranolazine	P-glycoprotein/ABCB1 Substrates serum levels can rise.
RifAMPin	Fexofenadine's serum concentration can drop. Fexofenadine's serum levels may rise in response to RifAMPin.
ROPINIRole	CNS Depressants may enhance the sedative effect of ROPINIRole.
Rotigotine	CNS Depressants may enhance the sedative effect of Rotigotine.
Rufinamide	May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.
Selective Serotonin Reuptake Inhibitors	CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.
Solriamfetol	Sympathomimetics may enhance the hypertensive effect of Solriamfetol.
Spironolactone	May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.
Sympathomimetics	Could intensify the hazardous or harmful effects of other sympathomimetics.
Tedizolid	Could make sympathomimetics' hypertensive effects stronger. The tachycardic impact of sympathomimetics may be increased by tedizolid.
Teriflunomide	May raise the level of OATP1B1/1B3 (SLCO1B1/1B3) Substrates in the serum.
Tetrahydrocannabinol	May enhance the CNS depressant effect of CNS Depressants.
Tetrahydrocannabinol and Cannabidiol	May enhance the CNS depressant effect of CNS Depressants.
Thiazide and Thiazide-Like Diuretics	Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics.
Topiramate	Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.
Trimeprazine	May enhance the CNS depressant effect of CNS Depressants.
Urinary Acidifying Agents	May decrease the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).
Verapamil	Fexofenadine serum concentration can rise.
Risk Factor D (Consider therapy modification)
Antacids	Fexofenadine's serum concentration can drop. Administration of fexofenadine and antacids containing aluminium or magnesium should be separated. Calcium carbonate, magnesium, and sodium bicarbonate are exceptions.
Benzylpenicilloyl Polylysine	Antihistamines may reduce Benzylpenicilloyl Polylysine's ability to diagnose. Management: Delay testing until systemic antihistaminic effects have subsided and discontinue systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing. To determine whether permanent antihistaminic effects exist, a histamine skin test may be utilised.
Benzylpenicilloyl Polylysine	Alpha-/Beta-Agonists may lessen the Benzylpenicilloyl Polylysine's ability to diagnose. Management: To evaluate a patient's capacity to mount a wheal and flare response, consider using a histamine skin test as a positive control.
Blonanserin	CNS Depressants may enhance the CNS depressant effect of Blonanserin.
Buprenorphine	CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.
Chlormethiazole	May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.
Cocaine (Topical)	May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.
Droperidol	May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Exceptions to this monograph are discussed in further detail in separate drug interaction monographs.
Flunitrazepam	CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.
Hyaluronidase	Antihistamines may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.
HYDROcodone	CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Linezolid	May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available.
Methotrimeprazine	CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.
Opioid Agonists	CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
OxyCODONE	CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Perampanel	May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.
Pramlintide	May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.
Secretin	Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.
Serotonin/Norepinephrine Reuptake Inhibitors	Alpha-/Beta-Agonists' tachycardic impact may be boosted. The vasopressor impact of alpha/beta agonists may be enhanced by serotonin/norepinephrine reuptake inhibitors.
Sodium Oxybate	May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.
Suvorexant	CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.
Tapentadol	May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Tolvaptan	May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates.
Zolpidem	CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.
Risk Factor X (Avoid combination)
Aclidinium	May enhance the anticholinergic effect of Anticholinergic Agents.
Azelastine (Nasal)	CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).
Bromperidol	May enhance the CNS depressant effect of CNS Depressants.
Cimetropium	Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium.
Eluxadoline	Anticholinergic Agents may enhance the constipating effect of Eluxadoline.
Ergot Derivatives	Alpha-/Beta-Agonists' hypertensive effects might be amplified. Alpha-/Beta-Agonists' vasoconstrictive effects may be strengthened by ergot derivatives. Exceptions: Mesylates of ergoloid; nicergoline
Glycopyrrolate (Oral Inhalation)	The anticholinergic effect of glycopyrrolate may be enhanced by anticholinergic agents (Oral Inhalation).
Glycopyrronium (Topical)	May strengthen an anticholinergic agent's anticholinergic action.
Iobenguane Radiopharmaceutical Products	Iobenguane radiopharmaceutical products' therapeutic effects may be lessened by alpha-/beta-agonists (indirect-acting). Treatment: Before administering iobenguane, stop taking any medications that could impede or interfere with catecholamine transport or uptake for at least five biological half-lives. After each dose of iobenguane, wait at least 7 days before administering these medications.
Ipratropium (Oral Inhalation)	May enhance the anticholinergic effect of Anticholinergic Agents.
Levosulpiride	Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride.
Monoamine Oxidase Inhibitors	Might make alpha-/beta-agonists' hypertensive effects more pronounced (Indirect-Acting). Although this is the expected mode of action for linezolid, management guidelines are different from those for other monoamine oxidase inhibitors. Details can be found in linezolid-specific monographs. Exceptions: Tedizolid; linezolid.
Orphenadrine	CNS Depressants may enhance the CNS depressant effect of Orphenadrine.
Oxatomide	May enhance the anticholinergic effect of Anticholinergic Agents.
Oxomemazine	May enhance the CNS depressant effect of CNS Depressants.
Paraldehyde	CNS Depressants may enhance the CNS depressant effect of Paraldehyde.
Potassium Chloride	Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.
Potassium Citrate	Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.
Revefenacin	Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin.
Thalidomide	CNS Depressants may enhance the CNS depressant effect of Thalidomide.
Tiotropium	Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.
Umeclidinium	May enhance the anticholinergic effect of Anticholinergic Agents.

Monitoring parameters:

Monitor the response to therapy, heart rate, and blood pressure.
Closed monitoring may be required in patients with angina and ischemic heart disease.

How to administer Fexofenadine and pseudoephedrine?

Administer the tablets on an empty stomach as a whole without crushing or chewing them. Avoid taking the drug with food

Mechanism of action of Fexofenadine and pseudoephedrine (Telfast D):

Fexofenadine

It affects the digestive system, blood vessels, and respiratory system's H1 receptors.

Pseudoephedrine:

It acts directly on alpha-adrenergic receptors, causing vasoconstriction in the nasal and respiratory mucosa.
It also causes dilation of the bronchial smooth muscle beta-adrenergic receptors.

Talk to individual agents.

International Brand Names of Fexofenadine and pseudoephedrine:

Allegra-D 12 Hour
Allegra-D 24 Hour
Allegra-D
Alcreas D
Alerfedine D
Alexia D
Alexia-D
Allegra D
Allegra-D
Allexofedrin D
Altiva-D
Dellegra
Dinafex Plus
Fenofex
Fexet-d
Fexo-d
Fexofed
Restaler D
Rinolast D
Sardin Plus
Telfast D
Telfast Decongestant
Telfast Plus
Telfast-D
Telfex-d
Vantydin

Fexofenadine and pseudoephedrine Brand Names in Pakistan:

Fexofenadine and pseudoephedrine Tablets 60 mg in Pakistan
Aloc D	Bosch Pharmaceuticals (Pvt) Ltd.
Axodine-D	Gray`S Pharmaceuticals
Fastec-D	Panacea Pharmaceuticals
Fenoxin Cf	Jawa Pharmaceuticals(Pvt) Ltd.
Fexet D	Getz Pharma Pakistan (Pvt) Ltd.
Fexo-D	Hilton Pharma (Pvt) Limited
Fexofin	Bio Labs (Pvt) Ltd.
Fexofin D	Bio Labs (Pvt) Ltd.
Fexota Plus	Orta Labs. (Pvt) Ltd.
Genfix-D	Genix Pharma (Pvt) Ltd
Regofast D	Regent Laboratories Ltd.
Sizzle D	Wilshire Laboratories (Pvt) Ltd.
Telfast-D	Sanofi Aventis (Pakistan) Ltd.
Telfex-D	Polyfine Chempharma (Pvt) Ltd.

Telfast D (Fexofenadine and pseudoephedrine) - Uses, Dose, Brands

Fexofenadine and pseudoephedrine Uses:

Seasonal allergic rhinitis:

Fexofenadine and pseudoephedrine (Telfast D) Dose in Adults

Fexofenadine and pseudoephedrine (Telfast D) Dose in the treatment of Seasonal allergic rhinitis: Oral:

Dose in Children:

Pregnancy Risk Factor C

Use of pseudoephedrine and fexofenadine during breastfeeding

Dose in Kidney Disease:

Fexofenadine 60 mg/pseudoephedrine 120 mg 12 Hour:

Fexofenadine 180 mg/pseudoephedrine 240 mg 24 Hour:

Dose in Liver disease:

Side effects of Fexofenadine and pseudoephedrine (Telfast D):

Contraindications to Fexofenadine and pseudoephedrine (Telfast D):

Warnings and precautions

Cardiovascular disease

Diabetes:

Increased intraocular pressure

Prostatic hyperplasia/urinary block:

Renal impairment

Seizure disorder:

Thyroid dysfunction:

Monitoring parameters:

How to administer Fexofenadine and pseudoephedrine?

Mechanism of action of Fexofenadine and pseudoephedrine (Telfast D):

International Brand Names of Fexofenadine and pseudoephedrine:

Fexofenadine and pseudoephedrine Brand Names in Pakistan:

Fexofenadine and pseudoephedrine Tablets 60 mg in Pakistan

Recent Posts

Related Posts